{"id":4486,"date":"2025-03-31T18:12:10","date_gmt":"2025-03-31T18:12:10","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/zuclopenthixol-txt\/"},"modified":"2025-03-31T18:12:10","modified_gmt":"2025-03-31T18:12:10","slug":"zuclopenthixol-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/zuclopenthixol-txt\/","title":{"rendered":"Zuclopenthixol.txt"},"content":{"rendered":"

CLINICAL USE <\/H3> Antipsychotic for schizophrenia and other psychoses

DOSE IN NORMAL RENAL FUNCTION <\/H3> Schizophrenia and paranoid psychoses: Oral: 20\u201330 mg daily in divided doses; maximum 150 mg daily Maintenance:
  • 20 to 50 &nbsp &nbsp : mg daily Deep IM: 200\u2013500 mg every 1\u20134 weeks Maximum: 600 mg weekly Acute psychoses: (Clopixol Acuphase) Deep IM: 50\u2013150 mg, repeated if required after 2\u20133 days Maximum 400 mg per course

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 401 (443 as acetate), (473.9 as hydrochloride), (555.2 as decanoate) <\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 98 <\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : Minimal (
  • 10 to 20 <\/LI>% unchanged drug and metabolites) <\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :
  • 10 to 20 &nbsp &nbsp : <\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp : 20\u201324

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Start with 50% of the dose and titrate slowly

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Not dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp : Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp: Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3> Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced hypotensive effects\n
  • Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids\n
  • Anti-arrhythmics: increased risk of ventricular arrhythmias with anti- arrhythmics that prolong the QT interval\n
  • Antidepressants: increased level of tricyclics\n
  • Anti-epileptics: anticonvulsant effect antagonised\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine\n
  • Antipsychotics: avoid concomitant use of clozapine with depot preparations in case of neutropenia\n
  • Antivirals: concentration possibly increased with ritonavir Anxiolytics and hypnotics: increased sedative effects\n
  • Sibutramine: increased risk of CNS toxicity \u2013 avoid concomitant use Avoid concomitant use with drugs that prolong the QT interval

    ADMINISTRATION <\/H3>

    Reconstition<\/H4> \u2013

    Route <\/H4> Oral, IM

    Rate of Administration <\/H4> \u2013

    Comments<\/H4> \u2013

    OTHER INFORMATION <\/H4> May cause hypotension and excessive sedation Increased CNS sensitivity in renally impaired patients \u2013 start with small doses as can accumulate Peak levels occur 3\u20136 hours after oral administration .the liver. It can be used in renal failure at normal doses with caution.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Antipsychotic for schizophrenia and other psychoses DOSE IN<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4486","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4486"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4486\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}